Jumio Recognized for Cutting Edge Fraud Prevention in 13th Annual Global InfoSec Awards
Article content
Article content
SUNNYVALE, Calif. — Jumio, the leading provider of automated, AI-driven biometric identity verification, risk signals and compliance solutions, today announced its recognition as a Cutting Edge Fraud Prevention Solution by Cyber Defense Magazine as part of the 13th annual Global InfoSec Awards.
Article content
Jumio was recognized for its innovative approach to identity verification and fraud prevention at a time when sophisticated AI-driven cyber threats are accelerating. The Jumio Platform combines advanced technologies, including AI, biometrics, liveness detection and connected intelligence to combat fraud and ensure businesses can establish and maintain trust throughout the user lifecycle. Jumio's multi-layered defense strategy tackles a wide range of attack types and is backed by an expansive patent portfolio spanning nearly 100 unique patent families and ensures that businesses using Jumio's services remain protected in an ever-evolving fraud landscape.
Article content
Article content
'In a world where identity fraud tactics grow more sophisticated, this award reinforces our dedication to empowering organizations with smarter, more secure ways to trust the people they do business with,' said Jumio CEO Robert Prigge.
Article content
'Jumio is absolutely worthy of this coveted award as it embodies three major features we judges look for in winners: understanding tomorrow's threats, providing a cost-effective solution and innovating in unexpected ways that can help mitigate cyber risk and get one step ahead of the next breach,' said Gary S. Miliefsky, publisher of Cyber Defense Magazine.
Article content
Jumio helps organizations to know and trust their customers online. From account opening to ongoing monitoring, the Jumio Platform provides advanced identity verification, risk signals and compliance solutions that help you accurately establish, maintain and reassert trust.
Article content
Leveraging powerful technology including automation, biometrics, AI/machine learning, liveness detection and no-code orchestration with hundreds of data sources, Jumio helps you fight fraud and financial crime, onboard good customers faster and meet regulatory compliance including KYC and AML. Jumio has processed more than 1 billion transactions spanning over 200 countries and territories from real-time web and mobile transactions.
Article content
Based in Sunnyvale, California, Jumio operates globally with offices and representation in North America, Latin America, Europe, Asia Pacific and the Middle East and has been the recipient of numerous awards for innovation. Jumio is backed by Centana Growth Partners, Great Hill Partners and Millennium Technology Value Partners.
Article content
Cyber Defense Magazine is the premier source of cyber security news and information for InfoSec professions in business and government. We are managed and published by and for ethical, honest, passionate information security professionals. Our mission is to share cutting-edge knowledge, real-world stories and awards on the best ideas, products, and services in the information technology industry. We deliver electronic magazines every month online for free, and special editions exclusively for the RSA Conferences. CDM is a proud member of the Cyber Defense Media Group. Learn more about us at https://www.cyberdefensemagazine.com and visit https://www.cyberdefensetv.com and https://www.cyberdefenseradio.com to see and hear some of the most informative interviews of many of these winning company executives. Join a webinar at https://www.cyberdefensewebinars.com and realize that infosec knowledge is power.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
U.S. Media Contact
Allison Knight
10Fold Communications
jumio@10fold.com
806-570-9819
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
20-05-2025
- National Post
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025
Article content Company's AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. Article content Article content MOUNT LAUREL, N.J. — CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata ®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta ®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved only for newly diagnosed AML. Quizartinib does not target TKD resistance mutations, whereas Gilteritinib's efficacy on FLT3-ITD-D835 mutations is limited and it is not effective against the FLT3-ITD-F691 gatekeeper mutation, both of which are very common. Crenolanib (AROG/Pfizer) is an FLT3 inhibitor whose NDA submitted to the FDA does not address the indications above, whose NDA was previously rejected by the FDA, and which binds to FLT3 mutants less tightly than Gilteritinib. Consequently, there is a critical need for next-generation FLT3 inhibitors that can address all of these mutations. Article content At ASCO 2025, CCM Biosciences' presentation 'Novel, Potent and Selective Inhibitors Targeting FLT3 for AML Therapy' in the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant session (Abstract #: 6542, will report novel FLT3 inhibitors have been identified that can both target FLT3-ITD and potentially overcome mutational resistance to FDA-approved FLT3 inhibitors. These agents are significantly more effective than Gilteritinib and have significant potential clinical applications. Article content CCM Biosciences' novel, orally bioavailable FLT3 inhibitors (CCM-405 and CCM-445) are the first drug candidates to overcome both FLT3-ITD juxtamembrane domain and tyrosine kinase domain (TKD) mutational drug resistance (including D835Y, F691L), significantly outperforming the aforementioned current-generation inhibitors both in the absence and presence of resistance mutations. Other reported investigational drug candidates capable of addressing FLT3-ITD resistance mutations either have poor pharmacokinetics, significant off-target binding, or both. Article content CCM Biosciences is advancing clinical candidates from its FLT3 inhibitor program to investigational new drug (IND) filing this year for entry into clinical trials for both newly diagnosed FLT3-positive AML and relapsed/refractory FLT3-positive AML. Multiple failures in AML clinical trials from competitors in 2024 present an attractive landscape for clinical trials of these drug candidates. Article content The company is actively partnering with biotechnology and pharmaceutical companies for co-development rights in selected countries. CCM Biosciences, a sister company of the global chemical and pharmaceutical services company PMC Group, Inc., is also a Featured Exhibitor at ASCO 2025 — — and will be showcasing both its drug programs and the state-of-the-art platforms used to discover and develop them. Article content About CCM Biosciences CCM Biosciences is a diversified biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines within multiple corporate subsidiaries. CCM's patented drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, Physical Review, American Chemical Society journals, Biophysical Society journals, and Nature Publishing Group journals. These platforms are complemented by the contract research, development, and manufacturing organizations (CRDMO) at PMC Group, the sister company of CCM Biosciences and a global chemical and pharmaceutical company with ~$1 billion in annual revenue. Article content Article content Article content Article content Article content Article content
National Post
20-05-2025
- National Post
Jumio Survey Reveals Crumbling Consumer Trust in Digital Life Amid Surge in AI-Powered Fraud and Deepfakes
Article content Article content SUNNYVALE, Calif. — Jumio, the leader in AI-powered identity intelligence anchored in biometric authentication, automation and data-driven insights, today released the 2025 Jumio Online Identity Study, the fourth installment of its annual global consumer research. This year's results paint a stark picture: trust in digital life is crumbling under the weight of deepfakes, misinformation and cybercrime. Article content The study examined the views of more than 8,000 adult consumers, split evenly across the United States, the United Kingdom, Singapore, and Mexico. Sixty-nine percent of respondents say AI-powered fraud now poses a greater threat to personal security than traditional forms of identity theft, and confidence in online authenticity continues to erode amid growing fears of manipulated content and AI-driven deception. Article content Seven out of 10 global consumers (69%) indicated they are more skeptical of the content they see online due to AI-generated fraud than they were last year. Just 37% of consumers said they more strongly believe that most social media accounts are authentic compared to last year, and only 36% claimed they were more trusting of news they encounter online, despite the possibility of encountering deepfakes or manipulated content. Article content These are just a couple of findings that demonstrate a global shift toward distrust and anxiety in digital spaces. Article content The majority of respondents also cited day-to-day worries around a number of AI-powered fraud tactics, including: Article content This indicates that consumers increasingly recognize the risks of conducting life and business online, but may lack the tools or evidence needed to identify secure, authentic content. Article content 'As generative AI continues to lower the barrier for sophisticated scams, Jumio's findings highlight an urgent need for businesses to rethink digital identity protection — not only to reduce fraud, but also to preserve customer trust and digital engagement itself,' explained Bala Kumar, chief product and technology officer at Jumio. Article content In the absence of strong regulatory protections, consumers are taking matters into their own hands. When asked who they trust most to protect their personal data from AI-powered fraud, 93% said themselves, far more than those who trust government agencies (85%) or Big Tech (88%). But self-reliance does not mean consumers want to go it alone. In fact, when asked who should be most responsible for stopping AI-powered fraud, 43% pointed to Big Tech, compared to just 18% who chose themselves. Article content The 2025 Jumio Online Identity Study identifies this trust gap as symptomatic of a rapidly evolving threat landscape, where fraud-as-a-service (FaaS) ecosystems flourish across dark web marketplaces. These plug-and-play toolkits enable even novice fraudsters to launch sophisticated attacks using synthetic identities, deepfake videos, and botnet-driven account takeovers. Article content This shift is forcing companies to modernize fraud defenses and rethink how they protect consumers in an AI-driven world. In parallel, Jumio's research found that consumers are open to the additional steps this may require. Most respondents globally said they would be willing to spend more time completing comprehensive identity verification processes, especially in sectors where stakes are high, like banking and financial services (80%), government services (78%), and healthcare (76%). Article content As consumers continue to live, work, and play in digital spaces, enterprises must provide more sophisticated security to combat AI-powered fraud. Enterprises will have to adopt proactive strategies that blend cutting-edge verification, real-time monitoring, and a zero-trust approach to digital security from a technological standpoint. But strong technology alone isn't enough. Businesses must also earn consumer trust in these protections. Article content 'Our industry must develop the tools we need to stay ahead of the AI-fraud arms race, because traditional identity verification isn't going to cut it anymore. From multi-modal biometrics to connected data, Jumio is committed to putting the next generation of identity intelligence in the hands of enterprises,' explained Jumio CEO Robert Prigge. 'However, we must ensure we take consumers on this journey too. Building a trustworthy digital world depends on strong consumer education and transparency.' Article content The Jumio 2025 Online Identity Study surveyed 8,001 adult consumers evenly distributed across the United States, the United Kingdom, Singapore, and Mexico. Censuswide fielded the survey between April 9 and April 24, 2025. Censuswide abides by and employs members of the Market Research Society which is based on the ESOMAR principles and are members of The British Polling Council. Article content About Jumio Article content Jumio helps organizations to know and trust their customers online. From account opening to ongoing monitoring, the Jumio Platform provides AI-powered identity intelligence anchored in biometric authentication, automation and data-driven insights to accurately establish, maintain and reassert trust. Article content Leveraging powerful automated technology including biometric screening, AI/machine learning, liveness detection and no-code orchestration with hundreds of data sources, Jumio helps to fight fraud and financial crime, onboard customers faster and meet regulatory compliance including KYC and AML. Jumio has processed more than 1 billion transactions spanning over 200 countries and territories from real-time web and mobile transactions. Article content Based in Sunnyvale, Jumio operates globally with offices and representation in North America, Latin America, Europe, Asia Pacific, and the Middle East and has been the recipient of numerous awards for innovation. Jumio is backed by Centana Growth Partners, Great Hill Partners and Millennium Technology Value Partners. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
Cision Canada
15-05-2025
- Cision Canada
Canadian Banks and Regulators to Meet in Toronto Amid Shifting Economic and Regulatory Landscape
TORONTO, May 15, 2025 /CNW/ - Senior executives from Canada's major banks and financial institutions will join government regulators in Toronto next month to address fast-moving regulatory and economic changes at the 24th Annual Canadian Forum on Anti-Money Laundering and Financial Crime, hosted by the Canadian Institute. Taking place June 25–26, 2025, at the One King West Hotel, the forum comes at a pivotal moment for the financial sector. Escalating U.S. tariffs and changes to the U.S. Corporate Transparency Act are intensifying cross-border compliance challenges for Canadian institutions. In a March 2025 statement, the U.S. Department of the Treasury's Financial Crimes Enforcement Network (FinCEN) confirmed that foreign entities qualifying as "reporting companies" must submit Beneficial Ownership Information (BOI) under newly mandated deadlines. Canadian institutions will need to respond quickly to comply with evolving standards. "There's a lot changing," said Karen Creen, conference co-chair and Chief Compliance Officer & Chief AML Officer at First Nations Bank of Canada. "We've moved into Gen 2 reporting with FINTRAC. We have the FATF mutual evaluation coming. There's the new reporting of sanctioned property that's going to FINTRAC. There's a lot of moving pieces, as always in AML." Notable speakers at the forum include: Key Topics Include:
